Clinical Trial: A Phase I Study of JSKN021 in Advanced Solid Tumors

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617727) titled 'A Phase I Study of JSKN021 in Advanced Solid Tumors' on May 20.

Brief Summary: This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Solid Tumors

Intervention: DRUG: JSKN021

JSKN021 administered intravenously at selected dose levels according to protocol

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Published ...